Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL SEPSIS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL SEPSIS MARKET SIZE
2.2.1.1. VENDOR POSITIONING GRID
2.2.1.2. TECHNOLOGY LIFE LINE CURVE
2.2.1.3. TRIPOD DATA VALIDATION MODEL
2.2.1.4. MARKET GUIDE
2.2.1.5. MULTIVARIATE MODELLING
2.2.1.6. TOP TO BOTTOM ANALYSIS
2.2.1.7. CHALLENGE MATRIX
2.2.1.8. APPLICATION COVERAGE GRID
2.2.1.9. STANDARDS OF MEASUREMENT
2.2.1.10. VENDOR SHARE ANALYSIS
2.2.1.11. SALES VOLUME
2.2.1.12. DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.1.13. DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL SEPSIS MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 EPIDEMIOLOGY
5.1 INCIDENCE OF ALL BY GENDER
5.2 TREATMENT RATE
5.3 MORTALITY RATE
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
5.5 PATEINT TREATMENT SUCCESS RATES
6 PREMIUM INSIGHTS
6.1 PATENT ANALYSIS
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH HEMATOLOGISTS
6.8 INTERVIEWS WITH PHYSICIAN
6.9 OTHER KOL SNAPSHOTS
7 INDUSTRY INSIGHTS
8 REGULATORY SCENARIO
9 GLOBAL SEPSIS MARKET, BY PRODUCT
9.1 OVERVIEW
9.2 DIAGNOSIS
9.2.1.1. BY PRODUCT
9.2.1.2. INSTRUMENTS
9.2.1.2.1. MOLECULAR DIAGNOSTIC INSTRUMENT
9.2.1.2.1.1 MARKET SHARE (USD)
9.2.1.2.1.2 MARKET VOLUME (UNITS)
9.2.1.2.1.3 AVERAGE SELLING PRICE (ASP- USD)
9.2.1.2.2. IN-VITRO DIAGNOSTIC INSTRUMENT
9.2.1.2.2.1 MARKET SHARE (USD)
9.2.1.2.2.2 MARKET VOLUME (UNITS)
9.2.1.2.2.3 AVERAGE SELLING PRICE (ASP- USD)
9.2.1.2.3. POINT OF CARE TESTING INSTRUMENT
9.2.1.2.3.1 MARKET SHARE (USD)
9.2.1.2.3.2 MARKET VOLUME (UNITS)
9.2.1.2.3.3 AVERAGE SELLING PRICE (ASP- USD)
9.2.1.3. ASSAYS & REAGENTS
9.2.1.3.1. PCR-BASED KITS
9.2.1.3.1.1 MARKET SHARE (USD)
9.2.1.3.1.2 MARKET VOLUME (UNITS)
9.2.1.3.1.3 AVERAGE SELLING PRICE (ASP- USD)
9.2.1.3.2. IMMUNOASSAY-BASED KITS
9.2.1.3.2.1 MARKET SHARE (USD)
9.2.1.3.2.2 MARKET VOLUME (UNITS)
9.2.1.3.2.3 AVERAGE SELLING PRICE (ASP- USD)
9.2.1.3.3. OTHERS
9.2.1.4. BLOOD CULTURE MEDIA
9.2.1.4.1. BROTH
9.2.1.4.2. AGAR
9.2.1.4.3. OTHERS
9.2.1.5. SOFTWARE
9.2.1.6. BY METHOD
9.2.1.7. CONVENTIONAL DIAGNOSTICS
9.2.1.8. AUTOMATED DIAGNOSTICS
9.2.1.9. BY TECHNOLOGY
9.2.1.10. MICROBIOLOGY
9.2.1.11. MOLECULAR DIAGNOSTICS
9.2.1.11.1. POLYMERASE CHAIN REACTION
9.2.1.11.2. MICROARRAYS
9.2.1.11.3. PEPTIDE NUCLEIC ACID-FLUORESCENT IN SITU HYBRIDIZATION
9.2.1.11.4. SYNDROMIC PANEL-BASED TESTING
9.2.1.12. IMMUNOASSAYS
9.2.1.13. FLOW CYTOMETRY
9.2.1.14. BY USABILITY
9.2.1.15. LABORATORY TESTING
9.2.1.16. POINT-OF-CARE TESTING
9.3 THERAPEUTICS
9.3.1.1. BY TYPE
9.3.1.2. ANTIBIOTICS
9.3.1.2.1. CEFTRIAXONE
9.3.1.2.2. MEROPENEM
9.3.1.2.3. CEFTAZIDIME
9.3.1.2.4. CEFOTAXIME
9.3.1.2.5. CEFEPIME
9.3.1.2.6. PIPERACILLIN AND TAZOBACTAM
9.3.1.2.7. AMPICILLIN AND SULBACTAM
9.3.1.2.8. IMIPENEM/CILASTATIN
9.3.1.2.9. LEVOFLOXACIN
9.3.1.2.10. CLINDAMYCIN
9.3.1.3. INTRAVENOUS FLUID REPLACEMENT
9.3.1.4. INSULIN
9.3.1.5. CYTOKINE ANTAGONISTS
9.3.1.5.1. INTERLEUTIN-1 RECEPTOR ANTAGONIST(IL-1RA)
9.3.1.5.2. INTERLEUKIN-10(IL-10)
9.3.1.5.3. TNF-Α,IL-1Β,IL-6
9.3.1.5.4. IL-8
9.3.1.6. PRR ANTAGONIST
9.3.1.6.1. TLRS
9.3.1.6.2. TLR1/TLR2
9.3.1.6.3. TLR2/TLR6
9.3.1.6.4. NLRS
9.3.1.6.5. OTHERS
9.3.1.7. PATHOGEN-ASSOCIATED MOLECULAR ANTAGONISTS
9.3.1.8. RECOMBINANT HUMAN APC (RHAPC)
9.3.1.8.1. DROTRECOGIN ALFA
9.3.1.8.2. XIGRIS
9.3.1.8.3. OTHERS
9.3.1.9. RECOMBINANT HUMAN SOLUBLE THROMBOSIS REGULATORS
9.3.1.10. PENTOXIFYLLINE
9.3.1.11. CO-INHIBITING MOLECULAR INHIBITOR
9.3.1.11.1. CYTOTOXIC T LYMPHOCYTE ANTIGEN 4
9.3.1.11.2. T-CELL IMMUNOGLOBULIN AND MUCIN DOMAIN PROTEIN 3
9.3.1.11.3. OTHERS
9.3.1.12. OTHERS
9.3.1.13. BY ROUTE OF ADMINISTRATION
9.3.1.14. INTRAVENOUS
9.3.1.15. ORAL
9.3.1.16. OTHERS
10 GLOBAL SEPSIS MARKET, BY PATHOGEN
10.1 OVERVIEW
10.2 BACTERIAL SEPSIS
10.2.1.1. GRAM-NEGATIVE BACTERIAL SEPSIS
10.2.1.2. GRAM-POSITIVE BACTERIAL SEPSIS
10.3 FUNGAL SEPSIS
10.3.1.1. CANDIDIASIS
10.3.1.2. INVASIVE CANDIDIASIS
10.3.1.3. ASPERGILLUS
10.3.1.4. OTHERS
10.4 OTHERS
11 GLOBAL SEPSIS MARKET, BY DRUG TYPE
11.1 OVERVIEW
11.2 GENERIC
11.3 BRANDED
11.3.1.1. ROCEPHIN
11.3.1.2. MERREM
11.3.1.3. FORTAZ
11.3.1.4. CLAFORAN
11.3.1.5. MAXIPIME
11.3.1.6. ZOSYN
11.3.1.7. UNASYN
11.3.1.8. PRIMAXIN
11.3.1.9. LEVAQUIN
11.3.1.10. CLEOCIN
12 GLOBAL SEPSIS MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.3 PATHOLOGY & REFERENCE LABORATORIES
12.4 AMBULATORY SURGICAL CENTERS
12.5 DIAGNOSTIC LABORATORY
12.6 OTHERS
13 GLOBAL SEPSIS MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 OVERVIEW
13.3 DIRECT TENDER
13.4 RETAIL SALES
13.4.1.1. HOSPITAL PHARMACIES
13.4.1.2. RETAIL PHARMACIES
13.4.1.3. ONLINE PHARMACIES
14 GLOBAL SEPSIS MARKET, BY REGION
14.1 GLOBAL SEPSIS MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
14.2 NORTH AMERICA
14.2.1.1. U.S.
14.2.1.2. CANADA
14.2.1.3. MEXICO
14.3 EUROPE
14.3.1.1. GERMANY
14.3.1.2. FRANCE
14.3.1.3. U.K.
14.3.1.4. ITALY
14.3.1.5. SPAIN
14.3.1.6. RUSSIA
14.3.1.7. TURKEY
14.3.1.8. BELGIUM
14.3.1.9. NETHERLANDS
14.3.1.10. SWITZERLAND
14.3.1.11. REST OF EUROPE
14.4 ASIA-PACIFIC
14.4.1.1. JAPAN
14.4.1.2. CHINA
14.4.1.3. SOUTH KOREA
14.4.1.4. INDIA
14.4.1.5. AUSTRALIA
14.4.1.6. SINGAPORE
14.4.1.7. THAILAND
14.4.1.8. MALAYSIA
14.4.1.9. INDONESIA
14.4.1.10. PHILIPPINES
14.4.1.11. REST OF ASIA-PACIFIC
14.5 SOUTH AMERICA
14.5.1.1. BRAZIL
14.5.1.2. ARGENTINA
14.5.1.3. REST OF SOUTH AMERICA
14.6 MIDDLE EAST AND AFRICA
14.6.1.1. SOUTH AFRICA
14.6.1.2. SAUDI ARABIA
14.6.1.3. UAE
14.6.1.4. EGYPT
14.6.1.5. ISRAEL
14.6.1.6. REST OF MIDDLE EAST AND AFRICA
14.7 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
15 GLOBAL SEPSIS MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: GLOBAL
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
15.3 COMPANY SHARE ANALYSIS: EUROPE
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
15.5 MERGERS & ACQUISITIONS
15.6 NEW PRODUCT DEVELOPMENT & APPROVALS
15.7 EXPANSIONS
15.8 REGULATORY CHANGES
15.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
16 GLOBAL SEPSIS MARKET, SWOT AND DBMR ANALYSIS
17 GLOBAL SEPSIS MARKET, COMPANY PROFILE
17.1 ABBOTT
17.1.1.1. COMPANY OVERVIEW
17.1.1.2. REVENUE ANALYSIS
17.1.1.3. GEOGRAPHIC PRESENCE
17.1.1.4. PRODUCT PORTFOLIO
17.1.1.5. RECENT DEVELOPMENTS
17.2 BECKMAN COULTER (DANAHER)
17.2.1.1. COMPANY OVERVIEW
17.2.1.2. REVENUE ANALYSIS
17.2.1.3. GEOGRAPHIC PRESENCE
17.2.1.4. PRODUCT PORTFOLIO
17.2.1.5. RECENT DEVELOPMENTS
17.3 BD
17.3.1.1. COMPANY OVERVIEW
17.3.1.2. REVENUE ANALYSIS
17.3.1.3. GEOGRAPHIC PRESENCE
17.3.1.4. PRODUCT PORTFOLIO
17.3.1.5. RECENT DEVELOPMENTS
17.4 BIOMÉRIEUX
17.4.1.1. COMPANY OVERVIEW
17.4.1.2. REVENUE ANALYSIS
17.4.1.3. GEOGRAPHIC PRESENCE
17.4.1.4. PRODUCT PORTFOLIO
17.5 BIO-RAD LABORATORIES
17.5.1.1. COMPANY OVERVIEW
17.5.1.2. REVENUE ANALYSIS
17.5.1.3. GEOGRAPHIC PRESENCE
17.5.1.4. PRODUCT PORTFOLIO
17.5.1.5. RECENT DEVELOPMENTS
17.6 BRUKER CORPORATION
17.6.1.1. COMPANY OVERVIEW
17.6.1.2. REVENUE ANALYSIS
17.6.1.3. GEOGRAPHIC PRESENCE
17.6.1.4. PRODUCT PORTFOLIO
17.6.1.5. RECENT DEVELOPMENTS
17.7 CEPHEID
17.7.1.1. COMPANY OVERVIEW
17.7.1.2. REVENUE ANALYSIS
17.7.1.3. GEOGRAPHIC PRESENCE
17.7.1.4. PRODUCT PORTFOLIO
17.7.1.5. RECENT DEVELOPMENTS
17.8 CHEMBIO DIAGNOSTIC SYSTEMS
17.8.1.1. COMPANY OVERVIEW
17.8.1.2. REVENUE ANALYSIS
17.8.1.3. GEOGRAPHIC PRESENCE
17.8.1.4. PRODUCT PORTFOLIO
17.8.1.5. RECENT DEVELOPMENTS
17.9 NANOSPHERE, INC.
17.9.1.1. COMPANY OVERVIEW
17.9.1.2. REVENUE ANALYSIS
17.9.1.3. GEOGRAPHIC PRESENCE
17.9.1.4. PRODUCT PORTFOLIO
17.9.1.5. RECENT DEVELOPMENTS
17.1 ORTHO-CLINICAL DIAGNOSTICS
17.10.1.1. COMPANY OVERVIEW
17.10.1.2. REVENUE ANALYSIS
17.10.1.3. GEOGRAPHIC PRESENCE
17.10.1.4. PRODUCT PORTFOLIO
17.10.1.5. RECENT DEVELOPMENTS
17.11 F. HOFFMANN-LA ROCHE LTD
17.11.1.1. COMPANY OVERVIEW
17.11.1.2. REVENUE ANALYSIS
17.11.1.3. GEOGRAPHIC PRESENCE
17.11.1.4. PRODUCT PORTFOLIO
17.11.1.5. RECENT DEVELOPMENTS
17.12 SIEMENS HEALTHCARE GMBH
17.12.1.1. COMPANY OVERVIEW
17.12.1.2. REVENUE ANALYSIS
17.12.1.3. GEOGRAPHIC PRESENCE
17.12.1.4. PRODUCT PORTFOLIO
17.12.1.5. RECENT DEVELOPMENTS
17.13 T2 BIOSYSTEMS, INC.
17.13.1.1. COMPANY OVERVIEW
17.13.1.2. REVENUE ANALYSIS
17.13.1.3. GEOGRAPHIC PRESENCE
17.13.1.4. PRODUCT PORTFOLIO
17.13.1.5. RECENT DEVELOPMENTS
17.14 THERMO FISHER SCIENTIFIC INC.
17.14.1.1. COMPANY OVERVIEW
17.14.1.2. REVENUE ANALYSIS
17.14.1.3. GEOGRAPHIC PRESENCE
17.14.1.4. PRODUCT PORTFOLIO
17.14.1.5. RECENT DEVELOPMENTS
17.15 LUMINEX CORPORATION
17.15.1.1. COMPANY OVERVIEW
17.15.1.2. REVENUE ANALYSIS
17.15.1.3. GEOGRAPHIC PRESENCE
17.15.1.4. PRODUCT PORTFOLIO
17.15.1.5. RECENT DEVELOPMENTS
17.16 IMMUNEXPRESS INC
17.16.1.1. COMPANY OVERVIEW
17.16.1.2. REVENUE ANALYSIS
17.16.1.3. GEOGRAPHIC PRESENCE
17.16.1.4. PRODUCT PORTFOLIO
17.16.1.5. RECENT DEVELOPMENTS
17.17 GENTIAN DIAGNOSTICS AS
17.17.1.1. COMPANY OVERVIEW
17.17.1.2. REVENUE ANALYSIS
17.17.1.3. GEOGRAPHIC PRESENCE
17.17.1.4. PRODUCT PORTFOLIO
17.17.1.5. RECENT DEVELOPMENTS
17.18 CALA MEDICAL
17.18.1.1. COMPANY OVERVIEW
17.18.1.2. REVENUE ANALYSIS
17.18.1.3. GEOGRAPHIC PRESENCE
17.18.1.4. PRODUCT PORTFOLIO
17.18.1.5. RECENT DEVELOPMENTS
17.19 ALIFAX S.R.L.
17.19.1.1. COMPANY OVERVIEW
17.19.1.2. REVENUE ANALYSIS
17.19.1.3. GEOGRAPHIC PRESENCE
17.19.1.4. PRODUCT PORTFOLIO
17.19.1.5. RECENT DEVELOPMENTS
17.2 ALPHA LABORATORIES
17.20.1.1. COMPANY OVERVIEW
17.20.1.2. REVENUE ANALYSIS
17.20.1.3. GEOGRAPHIC PRESENCE
17.20.1.4. PRODUCT PORTFOLIO
17.20.1.5. RECENT DEVELOPMENTS
17.21 BODITECH MED
17.21.1.1. COMPANY OVERVIEW
17.21.1.2. REVENUE ANALYSIS
17.21.1.3. GEOGRAPHIC PRESENCE
17.21.1.4. PRODUCT PORTFOLIO
17.21.1.5. RECENT DEVELOPMENTS
17.22 GENMARK DIAGNOSTICS
17.22.1.1. COMPANY OVERVIEW
17.22.1.2. REVENUE ANALYSIS
17.22.1.3. GEOGRAPHIC PRESENCE
17.22.1.4. PRODUCT PORTFOLIO
17.22.1.5. RECENT DEVELOPMENTS
17.23 SEEGENE
17.23.1.1. COMPANY OVERVIEW
17.23.1.2. REVENUE ANALYSIS
17.23.1.3. GEOGRAPHIC PRESENCE
17.23.1.4. PRODUCT PORTFOLIO
17.23.1.5. RECENT DEVELOPMENTS
17.24 EKF DIAGNOSTICS
17.24.1.1. COMPANY OVERVIEW
17.24.1.2. REVENUE ANALYSIS
17.24.1.3. GEOGRAPHIC PRESENCE
17.24.1.4. PRODUCT PORTFOLIO
17.24.1.5. RECENT DEVELOPMENTS
17.25 AXIS-SHIELD DIAGNOSTICS
17.25.1.1. COMPANY OVERVIEW
17.25.1.2. REVENUE ANALYSIS
17.25.1.3. GEOGRAPHIC PRESENCE
17.25.1.4. PRODUCT PORTFOLIO
17.25.1.5. RECENT DEVELOPMENTS
17.26 TRINITY BIOTECH
17.26.1.1. COMPANY OVERVIEW
17.26.1.2. REVENUE ANALYSIS
17.26.1.3. GEOGRAPHIC PRESENCE
17.26.1.4. PRODUCT PORTFOLIO
17.26.1.5. RECENT DEVELOPMENTS
*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
18 RELATED REPORTS
19 QUESTIONNAIRE
20 ABOUT DATA BRIDGE MARKET RESEARCH
